신장 및 비뇨기과 의료기기 시장 예측(2026-2032년)

The Nephrology & Urology Devices Market is projected to grow by USD 30.14 billion at a CAGR of 6.52% by 2032.

Nephrology and urology devices support diagnosis, monitoring, treatment, and long-term management of kidney, urinary tract, prostate, bladder, and reproductive-system conditions. Demand is being shaped by well-documented clinical and demographic pressures, including population aging, rising chronic kidney disease burden, diabetes and hypertension prevalence, urinary stone disease, benign prostatic hyperplasia, incontinence, and urologic cancers. Public health evidence consistently links chronic kidney disease with cardiovascular risk, diabetes, and hypertension, while urologic disorders remain common contributors to outpatient visits, hospital-based procedures, and quality-of-life impairment.

The device landscape spans dialysis equipment and consumables, ureteral stents, urinary catheters, lithotripsy systems, endoscopes, urodynamic systems, nephrostomy products, drainage systems, continence care devices, prostate treatment technologies, and robotic or image-guided surgical platforms. Healthcare systems are prioritizing earlier diagnosis, minimally invasive intervention, infection prevention, home-based therapy, and digitally enabled care pathways. As a result, innovation in nephrology and urology devices is increasingly centered on patient safety, clinical workflow efficiency, remote monitoring, biocompatible materials, procedure precision, and lower total cost of care without compromising outcomes.

Transformative Shifts in the Nephrology & Urology Device Landscape

The nephrology and urology devices landscape is undergoing structural transformation as care shifts from hospital-centered interventions toward integrated, minimally invasive, and outpatient-ready models. In nephrology, the expansion of home dialysis programs, wearable and portable kidney-care device research, improved water treatment systems, and remote patient monitoring are changing how chronic kidney disease and kidney failure are managed. These shifts respond to the need for continuity of care, reduced infection exposure, greater patient autonomy, and more efficient use of clinical capacity.

In urology, advances in flexible endoscopy, laser lithotripsy, digital imaging, single-use scopes, robotic assistance, and focal therapies are reshaping treatment of urinary stones, prostate disease, bladder conditions, and urologic cancers. Infection control remains a major driver, particularly for catheter-associated urinary tract infections and other device-related complications. Regulatory bodies and clinical guidelines continue to emphasize device sterility, traceability, patient risk stratification, and post-market surveillance. Sustainability is also emerging as a strategic priority, especially in high-volume dialysis and single-use device categories, where manufacturers and providers are evaluating waste reduction, energy efficiency, and responsible procurement.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative impact across nephrology and urology devices by improving image interpretation, procedural planning, patient monitoring, risk prediction, and workflow automation. In nephrology, AI-enabled analytics can support earlier identification of kidney function decline, dialysis adequacy monitoring, vascular access surveillance, fluid management, and hospitalization risk assessment when integrated with electronic health records, laboratory data, and connected dialysis systems. These applications are most valuable when they augment clinical decision-making and operate within validated governance frameworks.

In urology, AI is being applied to endoscopic image enhancement, stone recognition, prostate imaging support, bladder cancer detection workflows, robotic surgery assistance, urodynamic interpretation, and triage of hematuria or lower urinary tract symptoms. The impact is cumulative rather than isolated: better data capture improves algorithms, stronger algorithms improve clinical workflows, and improved workflows support more consistent patient outcomes. However, adoption depends on clinical validation, cybersecurity, interoperability, explainability, bias mitigation, and regulatory compliance. Industry leaders that treat AI as a regulated clinical capability rather than a standalone software feature are better positioned to build trust with physicians, patients, and health systems.

Key Regional Insights

Asia-Pacific is one of the most dynamic regions for nephrology and urology devices due to rapid population aging, rising diabetes and hypertension prevalence, expanding healthcare infrastructure, and growing access to minimally invasive care. China, India, Japan, South Korea, Australia, and ASEAN healthcare systems are investing in dialysis capacity, endourology platforms, imaging-guided procedures, digital hospitals, and localized manufacturing capabilities. Public and private providers are also improving access to chronic kidney disease management and urologic specialty services, although reimbursement variability, workforce shortages, and rural access gaps remain important constraints.

Europe is characterized by strict regulatory oversight, strong clinical guideline adherence, and broad uptake of minimally invasive urology, dialysis quality programs, and infection-control practices. The transition to the European medical device regulatory framework has increased documentation, clinical evidence, and post-market surveillance requirements, influencing product availability and development timelines. North America demonstrates strong adoption of advanced nephrology and urology technologies supported by established reimbursement pathways, specialist availability, clinical research activity, and mature hospital procurement systems. The United States and Canada continue to emphasize home dialysis, infection prevention, outpatient urologic procedures, robotic surgery, and digital health integration.

Latin America is seeing gradual improvement in access to dialysis services, stone management, and urologic diagnostics, with Brazil and Mexico acting as important healthcare hubs; however, uneven reimbursement, infrastructure limitations, and public-sector budget pressure influence adoption rates. Africa faces a high unmet need for kidney care and urologic intervention, with access shaped by workforce shortages, dialysis affordability, diagnostic gaps, and uneven distribution of specialist centers, creating demand for durable, cost-effective, and easy-to-maintain devices. The Middle East is expanding specialty care through tertiary hospitals, medical infrastructure investment, and demand for advanced urology and kidney care, particularly across Gulf countries where diabetes and hypertension management remains closely tied to kidney-care priorities.

Key Group Insights

NATO countries, while not a healthcare bloc, include many advanced medical systems where procurement resilience, cybersecurity, supply chain security, and standardization are increasingly relevant for connected nephrology and urology devices used in civilian and defense healthcare settings. The G7 remains influential in clinical innovation, reimbursement design, quality standards, and early adoption of AI-enabled diagnostics, robotic assistance, minimally invasive urology, and home-based kidney care. BRICS countries combine high disease burden, large patient populations, and increasing healthcare investment, making them important for scalable dialysis solutions, cost-efficient urology devices, local manufacturing, and public-sector access programs.

The European Union is a major regulatory and clinical evidence hub, with device adoption shaped by health technology assessment, procurement standards, sustainability objectives, and the requirements of the medical device regulatory framework. ASEAN countries are strengthening nephrology and urology care through expanding hospital networks, medical tourism, public health investment, and broader access to dialysis and endoscopic procedures. The region's diverse reimbursement systems and infrastructure maturity create varied adoption patterns, with urban centers typically leading in advanced urology platforms and chronic kidney disease services. The GCC is prioritizing high-acuity specialty hospitals, digital health infrastructure, and advanced surgical capabilities, supporting demand for premium urology systems, dialysis technologies, and integrated care pathways for diabetes- and hypertension-related kidney disease.

Key Country Insights

China is expanding kidney care capacity, urology specialization, local device manufacturing, and digital hospital infrastructure in response to aging, chronic disease, and urban healthcare demand. The United States leads adoption of advanced nephrology and urology devices through extensive specialty networks, outpatient surgical infrastructure, home dialysis initiatives, and strong use of robotic and image-guided urologic procedures. Japan's aging population and mature healthcare system support advanced continence care, dialysis quality, endoscopic urology, and precision technologies. India has a large unmet need for dialysis, kidney disease screening, stone management, and affordable urology devices, with adoption shaped by public-private care models, cost sensitivity, and expanding specialist access.

Germany benefits from advanced hospital infrastructure, strong engineering expertise, and broad availability of minimally invasive procedures, while the United Kingdom is focused on reducing waiting lists, improving outpatient pathways, and expanding diagnostic capacity for urologic disease and kidney care. Australia emphasizes high clinical standards, remote-care challenges, and chronic disease management, and France emphasizes regulated access, clinical evidence, and national care pathways. South Korea combines advanced hospital systems, strong technology adoption, and expertise in minimally invasive urologic procedures, while Italy and Spain combine aging populations with strong urology practice networks and demand for stone, prostate, continence, and dialysis solutions.

Canada emphasizes universal healthcare access, clinical guideline alignment, and quality-focused kidney care, with continued attention to home-based therapy and equitable access across geographically dispersed populations. Russia has substantial need for renal replacement therapy and urologic intervention across a large geography, with procurement, infrastructure, and localization considerations influencing device access. Brazil has a significant chronic kidney disease treatment burden and a large specialist base, supporting demand for dialysis technologies, endourology devices, and infection-control solutions. Mexico is expanding access to dialysis, urologic diagnostics, and minimally invasive procedures, with private-sector growth complementing public health services.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated innovation that addresses measurable pain points in nephrology and urology care: infection reduction, treatment precision, procedure efficiency, patient comfort, home-care enablement, and long-term device reliability. Product development should align with clinician workflows, reimbursement realities, sterilization requirements, and evidence expectations across major regulatory systems. Devices that reduce complications, support remote monitoring, and improve usability for both specialists and patients are more likely to gain durable adoption.

Manufacturers should invest in interoperable digital architecture, cybersecurity-by-design, AI validation, and post-market data systems to support connected dialysis platforms, urodynamic systems, endoscopy solutions, and surgical technologies. Regional strategies should be tailored rather than uniform: mature markets require evidence, automation, and outcomes support, while emerging markets often prioritize affordability, maintenance simplicity, training, and supply reliability. Partnerships with hospitals, dialysis centers, academic clinicians, and public health programs can accelerate training, generate real-world evidence, and improve responsible adoption. Sustainability should also be embedded into design and procurement narratives, particularly for high-volume consumables and energy-intensive kidney care systems.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified public health, regulatory, clinical, and industry sources. Inputs include peer-reviewed medical literature, clinical practice guidelines, public health agency publications, disease burden studies, regulatory frameworks, health technology assessment references, hospital procurement considerations, and documented trends in nephrology and urology care delivery. The analysis emphasizes evidence-backed drivers such as chronic kidney disease prevalence, diabetes and hypertension burden, population aging, urinary stone disease, infection prevention priorities, dialysis access, minimally invasive surgery adoption, and digital health integration.

The methodology excludes speculative market sizing, market share calculations, and forecasting. Instead, it synthesizes qualitative and evidence-based signals across device categories, regions, economic groups, and priority countries. Insights are reviewed for consistency with established clinical knowledge, regulatory direction, and healthcare system realities. Particular attention is given to regional access differences, reimbursement complexity, device safety requirements, AI governance, interoperability, and post-market evidence expectations in nephrology and urology devices.

Conclusion

Nephrology and urology devices are becoming central to modern healthcare as providers address the growing burden of kidney disease, urinary disorders, prostate conditions, stone disease, incontinence, and urologic cancers. The strongest opportunities are linked to safer procedures, earlier diagnosis, home-based kidney care, minimally invasive treatment, connected monitoring, AI-supported decision-making, and infection prevention. Regional adoption will continue to vary based on reimbursement, infrastructure, clinical workforce, regulation, and affordability, making localized strategies essential.

The industry's next phase will be shaped by evidence, usability, digital trust, regulatory readiness, and patient-centered design. Organizations that combine clinical performance with interoperability, service support, sustainable design, and region-specific access models will be best positioned to strengthen outcomes and support resilient nephrology and urology care systems worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Nephrology & Urology Devices Market, by Product

• 7.1. Introduction
• 7.2. Catheters
• 7.3. Dialysis Devices
  • 7.3.1. CrRt Systems
  • 7.3.2. Hemodiafilters
  • 7.3.3. Hemodialysis Systems
  • 7.3.4. Peritoneal Dialysis Systems
• 7.4. Endoscopes
• 7.5. Lithotripsy Devices
• 7.6. Ureteral Stents

8. Nephrology & Urology Devices Market, by Technology

• 8.1. Introduction
• 8.2. Acoustic Wave Technologies
• 8.3. Electrochemical Technologies
• 8.4. Laser Technologies
• 8.5. Ultrafiltration Technologies

9. Nephrology & Urology Devices Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Direct Sales
• 9.3. Distributors
• 9.4. Online Sales

10. Nephrology & Urology Devices Market, by Application

• 10.1. Introduction
• 10.2. Kidney Failure Management
• 10.3. Kidney Stone Removal
• 10.4. Prostate Disorders
• 10.5. Urinary Incontinence Management

11. Nephrology & Urology Devices Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Dialysis Centers
• 11.4. Home Care Settings
• 11.5. Hospitals

12. Nephrology & Urology Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Nephrology & Urology Devices Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Nephrology & Urology Devices Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Ambu A/S
• 16.2. AngioDynamics, Inc.
• 16.3. Asahi Kasei Corporation
• 16.4. B. Braun Melsungen AG
• 16.5. Baxter International Inc.
• 16.6. Becton, Dickinson and Company
• 16.7. Biodex Medical Systems, Inc.
• 16.8. Boston Scientific Corporation
• 16.9. Coloplast A/S
• 16.10. Convatec Group plc
• 16.11. Cook Group Incorporated
• 16.12. DirexGroup Ltd.
• 16.13. EDAP TMS S.A.
• 16.14. Fresenius Medical Care AG & Co. KGaA
• 16.15. Hollister Incorporated
• 16.16. Karl Storz SE & Co. KG
• 16.17. Laborie Medical Technologies Corp.
• 16.18. Lepu Medical Technology (Beijing) Co., Ltd.
• 16.19. Medtronic plc
• 16.20. Merit Medical Systems, Inc.
• 16.21. Nipro Corporation
• 16.22. Olympus Corporation
• 16.23. Richard Wolf GmbH
• 16.24. Siemens Healthineers AG
• 16.25. Stryker Corporation
• 16.26. Teleflex Incorporated
• 16.27. Terumo Corporation
• 16.28. Urovision GmbH